Navigation Links
Arena Pharmaceuticals to Present at the 13th Annual BIO CEO & Investor Conference
Date:2/9/2011

of lorcaserin; the Eisai collaboration and potential activities thereunder; and Arena's focus, goals, strategy, research and development programs, and ability to develop compounds and commercialize drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that could cause actual results to differ materially from the forward-looking statements include, but are not limited to, the following: the risk that regulatory authorities may not find data and other information related to Arena's clinical trials and other studies meet safety or efficacy requirements or are otherwise sufficient for regulatory approval; the timing of regulatory review and approval is uncertain; Arena's response to the complete response letter for the lorcaserin NDA may not be submitted when anticipated or the information provided in such response may not satisfy the FDA; the FDA may request other information prior to or after Arena resubmits the lorcaserin NDA or approval of the lorcaserin NDA; unexpected or unfavorable new data; risks related to commercializing new products; Arena's ability to obtain and defend its patents; the timing, success and cost of Arena's research and development programs; results of clinical trials and other studies are subject to different interpretations and may not be predictive of future results; clinical trials and other studies may not proceed at the time or in the manner Arena or others expect or at all; Arena's ability to obtain adequate funds; risks related to relying on collaborative agreements; the timing and receipt of payments and fees, if any, from collaborators; and satisfactory resolution of pending and any future litigation or other disagreements with others. Additional factors that could cause actual results to differ materially from those stated or implied by Arena's forward-looking statements are disclosed in Arena'
'/>"/>
SOURCE Arena Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Arena Pharmaceuticals to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
4. Arena Pharmaceuticals to Report Third Quarter 2008 Financial Results and to Host Conference Call and Webcast on Thursday, October 30, 2008
5. Arena Pharmaceuticals to Present at the Oppenheimer 19th Annual Healthcare Conference
6. Arena Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
7. Arena Pharmaceuticals Obtains Equity Financing Commitment of Up to $50 Million
8. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Monday, May 11, 2009
9. Arena Pharmaceuticals Announces First Quarter 2009 Financial Results
10. Arena Pharmaceuticals to Present at the 8th Annual Needham Life Sciences Conference
11. Arena Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... , Dec. 23, 2014  Rock Creek Pharmaceuticals, ... it has filed a Clinical Trial Application (CTA) with ... products Regulatory Agency (MHRA) seeking regulatory approval to initiate ... molecule, Anatabine Citrate. Contingent on the Company ... a Phase I trial to assess the safety, tolerability ...
(Date:12/22/2014)... , Dec. 22, 2014  Alternative Energy & ... it has signed a letter of intent to ... developed and patented a nanotechnology-based development platform used ... that enable rapid on-site collection and testing to ... health issues in an immediate, non-invasive and cost-effective ...
(Date:12/22/2014)... Fertility Associates of Memphis has announced a new ... network of more than 20 contributing fertility practices ... access to a national pool of frozen donor ... of Memphis is the only fertility clinic in the ... Dr. William Kutteh , director of Fertility Associates of ...
(Date:12/19/2014)... Dec. 19, 2014  Roche (SIX: RO, ROG; OTCQX: ... Inc. (Bina), a privately held company based in ... Bina provides a big data platform for centralized ... data. Bina,s proprietary on-market Genomic Management Solution, Bina-GMS ... to perform fast and scalable analyses to maximize ...
Breaking Biology Technology:Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 2Rock Creek Pharmaceuticals Files Clinical Trial Application in the UK for Clinical Trials of Anatabine Citrate Formulations 3ALNE Announces Intention To Acquire BioTechPharma 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3Roche acquires Bina Technologies and enters the genomic informatics market 2Roche acquires Bina Technologies and enters the genomic informatics market 3
... LigoCyte Pharmaceuticals,Inc., a vaccine company in Bozeman, ... an agreement for a $28 million venture ... its two lead vaccines,against norovirus and influenza., ... led by Forward Ventures, JAFCO,and Novartis Venture ...
... Track to Deliver First Biotech Product with ... Direct Consumer Benefits, ... a new, improved soybean oil trait from DuPont (NYSE: DD ... products currently on the market. The high oleic soybean,oil trait is ...
... MATK ) announced today the launch of the first ... omega-3 for brain, eye,and heart health. The first and ... with life,sDHA from Bimbo Bakeries USA is now,available at ... "This new launch from Bimbo Bakeries demonstrates the ...
Cached Biology Technology:LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series 'C' Financing Round 2LigoCyte Pharmaceuticals Finalizes Agreement for $28M Series 'C' Financing Round 3Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 2Research Confirms Better Oil from New DuPont High Oleic Soybean Trait 3Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3
(Date:12/11/2014)... SALEM, N.C. , Dec. 10, 2014  That blood ... for quite a while. Hypertension – the medical term for ... in the early 1800s, and the inflatable cuff that,s used ... That doesn,t, however, mean there,s nothing new about hypertension, its ... some long-held beliefs about the condition and the best ways ...
(Date:12/10/2014)... , Dec. 9, 2014  Valencell, a leader in ... seeing a staggering demand from its licensees for highly ... revealed, is not solely coming from fitness and health ... "A wearable is only as useful as ... is the ultimate driver in long-term mass consumer adoption ...
(Date:12/10/2014)... 2014 Research and Markets ( ... "Biometrics Market in Japan 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 The integration of biometrics ... banking and upgradation of the driver,s license is ... market. Besides the aforementioned projects, biometrics is being ...
Breaking Biology News(10 mins):Research points to need for new approaches to treatment of high blood pressure 2Research points to need for new approaches to treatment of high blood pressure 3Research points to need for new approaches to treatment of high blood pressure 4Wearable Technology Products Demand Highly Accurate Biometric Technology 2Biometrics Market in Japan 2014-2018: Key Vendors are DDS, Fujitsu, Hitachi and NEC 2
... happened to the chicken when she crossed the road is less ... used as fertilizer. , Organic arsenic is fed to poultry to ... arsenic is taken up by the tissue and the majority of ... feathers, droppings, and urine from under poultry houses -- is rich ...
... Could improve prediction of patient outcomes, lead to tailored ... good thing can be deadly. In some severely injured ... lethal, whole-body response, including bloodstream infection (sepsis) and multiple ... to harming is still mysterious, so doctors can't accurately ...
... structures with pharmaceutical potential in a species of red ... the coastline of Fiji in the south Pacific Ocean. ... to kill cancer cells, bacteria and the HIV virus, ... In fact, two of them exhibit anti-bacterial activity towards ...
Cached Biology News:Geoscientists follow arsenic from chicken feed to streambeds 2Study Unlocks Insects?Secret for Love in the Dark 2Study Unlocks Insects?Secret for Love in the Dark 3Seaweed yields new compounds with pharmaceutical potential 2Seaweed yields new compounds with pharmaceutical potential 3Seaweed yields new compounds with pharmaceutical potential 4
... DNase I, ds Qualified is a special ... be used for double stranded cleavage of DNA ... of Mg2+, the enzyme makes double strand breaks ... of the resulting fragments can be controlled by ...
... Ambion introduced the highly potent TURBO DNase (patent ... standard was set in DNA removal capabilities. TURBO ... I that is much more efficient than wild ... of unwanted DNA. TURBO DNase binds DNA substrates ...
... The IEC Centra CL3 series ... in typical research and clinical applications ... broad accessory package includes quick connect ... An advanced yet intuitive interface allows ...
Porcine Pulmonary Artery Endothelial Cells (PPAEC) (>500,000 cells)...
Biology Products: